Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Purilon is a sterile, high-viscosity hydrogel dressing developed by Coloplast, designed to facilitate autolytic debridement and maintain a moist wound-healing environment. The formulation primarily consists of purified water, sodium carboxymethylcellulose (CMC), and calcium alginate. Purilon works by a dual action: it hydrates dry necrotic tissue and slough, promoting the body's natural enzymatic breakdown of non-viable tissue, while the CMC and alginate components allow it to absorb wound exudate and debris. This balanced hydration helps prevent maceration of the surrounding skin while ensuring the wound bed remains moist to support granulation. It is typically indicated for the treatment of necrotic and sloughy wounds, including pressure ulcers, leg ulcers, non-infected diabetic foot ulcers, and minor burns.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Purilon.